KDR and neoplasm: Multi-targeted TKIs, such as sunitinib, inhibit the downstream signaling of receptors, including VEGFR, platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (c-Kit), and colony-stimulating factor -1 (CSF-1) receptor, preventing neoplastic proliferation and tumor angiogenesis [124].